TAMPA, FL, UNITED STATES, January 20, 2026 /EINPresswire.com/ — Today marks the official launch of Scale Up Blueprint™: 7 Essential Building Blocks for ...

Among patients with advanced melanoma, long-term data have shown that a personalized mRNA cancer vaccine, when combined with ...

Moderna and Merck's cancer vaccine reduced the risk of relapse of death for melanoma patients, five-year data from a Phase 2b ...

Industry leaders at JPM this week revealed which up-and-coming assets they’re watching from other companies in oncology and ...

A key number for Merck in the coming years is $70 billion. This is the mid-2030s revenue opportunity from potential new ...

Moderna pivots to infectious disease & oncology, targeting cash break-even by 2028. Click here to see why I rate MRNA stock a ...

Merck begins phase 3 KANDLELIT-007 trial of calderasib in combo Keytruda QLEX in certain patients with advanced NSCLC: Rahway, New Jersey Friday, January 9, 2026, 15:00 Hrs [IST] ...

Forbes contributors publish independent expert analyses and insights. Dr. Tracy Brower writes about joy, community and the future of work. This voice experience is generated by AI. Learn more. This ...

During a recent workshop, a senior executive said to me, “None of us knows how people will learn in this new era.” Lynda Gratton is a professor of management practice at London Business School and the ...

Radiation therapy combined with Keytruda increased T cell infiltration in HR+ and HER2-negative breast cancer, enhancing immune response. High-dose radiation with Keytruda led to increased ...